US4022758A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Isolation of coagulation factors I and VIII from biological material
Assignee: Phadia AB
•
Filing: 1975-07-30
•
Granted: 1977-05-10
•
Expires: 1995-07-30
Abstract
Abstract The blood coagulation factors I (fibrinogen) and VIII (antihemophilia factor, abbreviated AHF) are isolated in high yields from animal tissue materials such as blood or blood products (e.g. plasma) or plasma fractions by a procedure involving the essential step of adsorption (as in affinity chromatography) of at least one of these factors, in a liquid system, onto a water-insoluble gel matrix primarily composed of a cross-linked sulfated or sulfonated, gel-forming carbohydrate such as cross-linked dextran sulfate-agarose, cross-linked dextran sulfate-dextran, cross-linked heparin-agarose and other such gel matrix-providing substances.
Inventors
- 👤 Lars-Olov Andersson
- 👤 Hakan Gunnar Borg
- 👤 Nanna Forsman
- 👤 Gunnar Hanshoff
- 👤 Goran Lindroos
- 👤 Maggie Miller-Andersson
- 👤 Elisabeth Charlotte Carling nee Ehrenberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:41
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83; Y10S530/831
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
108 words
In a method of isolating at least one of the blood coagulation factors fibrinogen and the antihemophilia factor VIII, from an animal blood tissue product containing fibrinogen or both of these factors, the improvement which comprises (i) contacting a water-insoluble gel matrix adsorbing agent selected from cross-linked dextran sulfate-dextran, cross-linked dextran sulfate-agarose, cross-linked dextran sulfate epichlorhydrin-agarose, dextran sulfate epichlorhydrin-cross-linked agarose, cross-linked chondroitin sulfate, cross-linked heparin-agarose, cross-linked heparin, cross-linked benzidine-2,2'-disulfonic acid-agarose, and cross-linked benzidine-2,2'-disulfonic acid-dextran, with said animal blood tissue product dissolved in an aqueous medium otherwise inert to the therein dissolved content of the said blood tissue product, and (ii) separating the non-adsorbed solution from the gel matrix.
Claim 2
Dependent Claim
108 words
In a method of isolating at least one of the blood coagulation factors fibrinogen and the antihemophilia factor VIII, from an animal blood tissue product containing fibrinogen or both of these factors, the improvement which comprises (i) contacting a water-insoluble gel matrix adsorbing agent selected from cross-linked dextran sulfate-dextran, cross-linked dextran sulfate-agarose, cross-linked dextran sulfate epichlorhydrin-agarose, dextran sulfate epichlorhydrin-cross-linked agarose, cross-linked chondroitin sulfate, cross-linked heparin-agarose, cross-linked heparin, cross-linked benzidine-2,2'-disulfonic acid-agarose, and cross-linked benzidine-2,2'-disulfonic acid-dextran, with said animal blood tissue product dissolved in an aqueous medium otherwise inert to the therein dissolved content of the said blood tissue product, and (ii) separating the non-adsorbed solution from the gel matrix.
Claim 3
Dependent Claim
15 words
A method as claimed in claim 1, wherein said animal blood tissue product is blood.
Claim 4
Dependent Claim
15 words
A method as claimed in claim 2, wherein said blood tissue product is human blood.
Claim 5
Dependent Claim
22 words
A method as claimed in claim 3, wherein said blood tissue product is either fresh or outdated plasma, or a plasma fraction.
Claim 6
Dependent Claim
13 words
A method as claimed in claim 4, wherein said adsorbed factor is fibrinogen.
Claim 7
Dependent Claim
16 words
A method as claimed in claim 5, wherein said blood tissue product is a plasma fraction.
Claim 8
Dependent Claim
28 words
A method as claimed in claim 6, wherein said blood tissue product is selected from Cohn fraction I-O, Cohn fraction I paste, or Cohn (method 6) fraction I.
Claim 9
Dependent Claim
55 words
A method as claimed in claim 4, wherein said blood tissue product contains fibrinogen and the antihemophilia factor, and the fibrinogen is adsorbed therefrom on said adsorbing agent, and the method further comprises separating the gel matrix adsorbing agent bearing said fibrinogen adsorbate from the non-adsorbed remainder of the solution of said blood tissue product.
Claim 10
Dependent Claim
54 words
A method as claimed in claim 8, wherein the fibrinogen is separated from said gel matrix adsorbing agent by eluting the fibrinogen from said agent with an aqueous solution of a buffering agent for the fibrinogen and inert to the adsorbing agent, to provide a solution of the fibrinogen in that aqueous buffer solution.
Claim 11
Dependent Claim
33 words
A method as claimed in claim 9, wherein the fibrinogen is eluted from said gel matrix adsorbing agent by elution with an aqueous solution of from about 1M to about 2M sodium chloride.
Claim 12
Dependent Claim
28 words
A method as claimed in claim 10, wherein the fibrinogen is precipitated from said solution of it by admixing in said solution a water-soluble precipitant for the fibrinogen.
Claim 13
Dependent Claim
25 words
A method as claimed in claim 8, wherein the antihemophilia factor is separated from the non-adsorbed remainder of said solution of said blood tissue product.
Claim 14
Dependent Claim
39 words
A method as claimed in claim 12, wherein the antihemophilia factor is separated from said non-adsorbed remainder solution by addition of sodium citrate to said remainder solution, and the thus precipitated antihemophilia factor is separated from the resulting mixture.
Claim 15
Dependent Claim
80 words
A method as claimed in claim 8, wherein said blood tissue product is Cohn fraction I paste and it is dissolved in an aqueous solution of an inorganic salt solvent buffer for said paste at about pH 6.8, and the adsorbing agent gel matrix is cross-linked dextran sulfate epichlorhydrin treated agarose; and the antihemophilia factor is separated from said non-adsorbed remainder of the solution of said paste by addition of sodium citrate to said non-adsorbed remainder at about pH 7.1.
Claim 16
Dependent Claim
61 words
A method as claimed in claim 1, wherein said blood tissue product is brought in contact with said water-insoluble gel matrix adsorbing agent for a time sufficient for the said fibrinogen to be adsorbed by said adsorbing agent; said agent being used in a quantity sufficient to adsorb at least about 15 percent of said fibrinogen from said starting tissue product.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-05-09 | 1980-11-08 | 1981-05-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-05-09 | 1984-11-08 | 1985-05-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-05-09 | 1988-11-08 | 1989-05-10 | $7700.00 | Window Closed / Lapsed |